Insider Buying: Corcept Therapeutics (NASDAQ:CORT) Director Purchases $3,314,000.00 in Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) Director G Leonard Baker, Jr. acquired 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The shares were acquired at an average cost of $33.14 per share, for a total transaction of $3,314,000.00. Following the purchase, the director directly owned 1,146,631 shares of the company’s stock, valued at $37,999,351.34. This represents a 9.55% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link.

Corcept Therapeutics Price Performance

Shares of NASDAQ CORT opened at $34.64 on Friday. Corcept Therapeutics Incorporated has a fifty-two week low of $28.66 and a fifty-two week high of $117.33. The company has a 50 day simple moving average of $37.46 and a two-hundred day simple moving average of $61.87. The company has a market capitalization of $3.68 billion, a price-to-earnings ratio of 42.24 and a beta of 0.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 2.92.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.13). The business had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $254.94 million. Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. Corcept Therapeutics’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.26 earnings per share. Analysts expect that Corcept Therapeutics Incorporated will post 1.36 EPS for the current fiscal year.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Director G. Leonard Baker Jr. bought 100,000 shares (~$3.3M) at about $33.14 on March 17, a meaningful insider purchase that signals management confidence and can support short‑term demand. Read More.
• Neutral Sentiment: Short‑interest reports for March 19–20 show effectively zero reported short interest (days‑to‑cover ≈ 0), which appears anomalous and likely reflects reporting quirks rather than a genuine absence of short sellers; this creates uncertainty about short‑seller pressure signals.
• Negative Sentiment: Multiple shareholder‑rights firms (Hagens Berman, Schall, DJS, Pomerantz, Rosen, Glancy, others) have issued class‑action/lead‑plaintiff notices tied to alleged FDA issues and a federal court patent loss — a concentrated legal PR wave that raises litigation risk, could increase future liabilities, and likely weighs on investor confidence. Read More. Read More.
• Negative Sentiment: Zacks Research sharply cut EPS forecasts across 2026–2027 and maintains a “Strong Sell” stance — analyst downgrades and lower near‑term earnings expectations increase downside pressure on valuation and can amplify selling if guidance or legal exposure worsens. Read More.

Analyst Ratings Changes

A number of equities research analysts have recently commented on CORT shares. Canaccord Genuity Group increased their target price on Corcept Therapeutics from $99.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, January 23rd. Zacks Research lowered Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target on the stock. in a research note on Wednesday, December 31st. Weiss Ratings reissued a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. Finally, UBS Group assumed coverage on shares of Corcept Therapeutics in a research note on Tuesday, December 16th. They set a “neutral” rating and a $95.00 price objective for the company. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Corcept Therapeutics has an average rating of “Hold” and a consensus price target of $77.17.

Institutional Trading of Corcept Therapeutics

Several institutional investors have recently added to or reduced their stakes in CORT. Pathstone Holdings LLC grew its holdings in shares of Corcept Therapeutics by 0.8% in the third quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock valued at $1,497,000 after purchasing an additional 144 shares in the last quarter. Campbell Newman Asset Management Inc. grew its stake in shares of Corcept Therapeutics by 0.5% in the 3rd quarter. Campbell Newman Asset Management Inc. now owns 35,530 shares of the biotechnology company’s stock worth $2,953,000 after buying an additional 170 shares in the last quarter. Clearstead Advisors LLC grew its stake in shares of Corcept Therapeutics by 163.6% in the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after buying an additional 193 shares in the last quarter. Gould Capital LLC increased its holdings in shares of Corcept Therapeutics by 50.0% in the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock worth $50,000 after buying an additional 200 shares during the last quarter. Finally, Advisors Asset Management Inc. increased its holdings in shares of Corcept Therapeutics by 1.3% in the 2nd quarter. Advisors Asset Management Inc. now owns 18,935 shares of the biotechnology company’s stock worth $1,390,000 after buying an additional 237 shares during the last quarter. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.